Jin‐Yuan Shih

<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib

James Bean, Cameron Brennan, Jin‐Yuan Shih et al. · Proceedings of the National Academy of Sciences · 2007 · 1.6K citations

Medicine, Genetics, Oncology +17

Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of <i>TWIST</i> Gene Expression

Hui‐Wen Lo, Sheng-Chieh Hsu, Weiya Xia et al. · Cancer Research · 2007 · 627 citations · Full text

Medicine, Cell Biology, Oncology +17

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 613 citations · Full text

Medicine, Oncology, Pharmacology +12

Pretreatment Epidermal Growth Factor Receptor ( <i>EGFR</i> ) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer

Kang‐Yi Su, Hsuan‐Yu Chen, Ker-Chau Li et al. · Journal of Clinical Oncology · 2012 · 494 citations · Full text

Medicine, Oncology, Pharmacology +15

Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

Jenn‐Yu Wu, Chong‐Jen Yu, Yeun‐Chung Chang et al. · Clinical Cancer Research · 2011 · 466 citations · Full text

Medicine, Oncology, Pharmacology +14